Domů › Mnohočetný myelom › Minnesota › Rochester
Klinické studie Mnohočetný myelom v Rochester, MN
24 studií pro Mnohočetný myelom hledá účastníky v lokalitách v Rochester a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Probíhá nábor
- Mayo Clinic in Rochester, Rochester
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
Probíhá náborObservační studie
- Mayo Clinic in Rochester, Rochester
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 3
- Mayo Clinic, Rochester
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 3
- Mayo Clinic Rochester, Rochester
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Probíhá náborFáze 3
- Mayo Clinic, Rochester
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Probíhá náborFáze 4
- Mayo Clinic Rochester, Rochester
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Probíhá náborFáze 2/3
- Mayo Clinic Hospital Rochester /ID# 277886, Rochester
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1
- Mayo Clinic in Rochester, Rochester
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 2
- Mayo Clinic in Rochester, Minnesota, Rochester
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1
- Mayo Clinic Rochester, Rochester
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 2
- Mayo Clinic in Rochester, Rochester
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Probíhá náborFáze 3
- Mayo Clinic in Rochester, Rochester
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Probíhá náborFáze 1
- Mayo Clinic - Transplant Center - Rochester, Rochester
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Probíhá náborFáze 1/2
- Research Site, Rochester
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 2
- Mayo Clinic - Minnesota, Rochester
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Probíhá náborFáze 1
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1
- Mayo Clinic - Rochester /ID# 251164, Rochester
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Probíhá náborFáze 1
- Mayo Clinic, Rochester
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Probíhá náborFáze 1/2
- Mayo Clinic in Rochester, Rochester
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Probíhá náborFáze 3
- Mayo Clinic in Rochester, Rochester
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Probíhá náborFáze 1
- Mayo Clinic in Rochester, Rochester
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Probíhá nábor
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Mayo Clinic, Rochester
Family Study of Lymphoproliferative Disorders
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Mayo Clinic, Rochester
Studie Mnohočetný myelom v jiných městech
- New York City, NY60 studií
- Boston, MA42 studií
- Atlanta, GA41 studií
- Houston, TX38 studií
- Durham, NC37 studií
- Nashville, TN32 studií
- Denver, CO27 studií
- St. Louis, MO24 studií
- Columbus, OH24 studií
- Baldwin Park, CA23 studií
- Chicago, IL22 studií
- Seattle, WA22 studií
Další studie v Rochester
- Rakovina prsu42 studií
- Nemalobuněčný plicní karcinom37 studií
- Metastatický karcinom31 studií
- Rakovina (všechny typy)30 studií
- Kolorektální karcinom29 studií
- Rakovina vaječníků29 studií
- Rakovina prostaty22 studií
- Srdeční selhání22 studií
- Rakovina slinivky břišní22 studií
- Rakovina plic20 studií
- Rakovina endometria20 studií
- Chronická lymfocytární leukemie19 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.